Biotargets for mediation of arsenic–induced coronary heart disease by calycosin. Issue 1 (31st December 2022)

• Record Type: Journal Article
• Authors: Xu, Hongyuan; Qin, Lixiu; Nie, Litao; Li, Lin; Guo, Peng; Chen, Yizhao; Huang, Chuang; Su, Min; Yang, Bin
• Is Part Of: Food and agricultural immunology. Volume 33:Issue 1(2022)
• Page Start: 207
• Page End: 219
• Publication Date: 2022-12-31
• Subjects: Calycosin -- Coronary heart disease -- Arsenic -- Network pharmacology -- Biotarget; Immunochemistry -- Periodicals; Food -- Analysis -- Periodicals; Immunoassay -- Periodicals; 616.079
• DOI: 10.1080/09540105.2022.2053947
• Languages: English
• ISSNs: 0954-0105

Abstract

ABSTRACT: Arsenic (As), an environmental pollutant, is a highly poisonous metalloid. Accumulated evidence has shown the association between As exposure and elevated risk of the development of coronary heart disease (CHD). Calycosin, a beneficial flavonoid, has demonstrated cardioprotective activities, including those against CHD, in preclinical studies. The anti-As-related CHD activity and mechanism of calycosin have not yet been elucidated. Here, we aimed to determine the core biotargets and molecular mechanisms of calycosin against As-interrelated CHD via integrated bioinformatic analysis, including network pharmacology and molecular docking. The network pharmacology data demonstrated 41 intersection genes of calycosin against As-related CHD, prior to the identification of 15 core targets. Additional in silico investigation indicated that mitogen-activated protein kinase-3 (MAPK3), epidermal growth factor receptor (EGFR), and interleukin-6 (IL6) were the primary pharmacological targets of calycosin for the treatment of As-related CHD. In addition, the therapeutic effects can be realized via cardioprotection-associated signaling pathways for reducing As-induced myocardial toxicity and impairment and boosting CHD functional reparation. In summary, calycosin mediates potent pharmacological effects in As-related CHD therapy functioning via multiple targets and multiple pathways. The results may eventually aid in promoting future clinical application after experimental verification.